Piros E T, Hales T G, Evans C J
Department of Psychiatry and Biobehavioral Sciences, University of California, School of Medicine, Los Angeles 90095, USA.
Neurochem Res. 1996 Nov;21(11):1277-85. doi: 10.1007/BF02532368.
Opioids modulate numerous central and peripheral processes including pain perception neuroendocrine secretion and the immune response. The opioid signal is transduced from receptors through G proteins to various different effectors. Heterogeneity exists at all levels of the transduction process. There are numerous endogenous ligands with differing selectivities for at least three distinct opioid receptors (mu, delta, kappa). G proteins activated by opioid receptors are generally of the pertussis toxin-sensitive Gi/Go class, but there are also opioid actions that are thought to involve Gq and cholera toxin-sensitive G proteins. To further complicate the issue, the actions of opioid receptors may be mediated by G-protein alpha subunits and/or beta gamma subunits. Subsequent to G protein activation several effectors are known to orchestrate the opioid signal. For example activation of opioid receptors increases phosphatidyl inositol turnover, activates K+ channels and reduces adenylyl cyclase and Ca2+ channel activities. Each of these effectors shows considerable heterogeneity. In this review we examine the opioid signal transduction mechanism. Several important questions arise: Why do opioid ligands with similar binding affinities have different potencies in functional assays? To which Ca2+ channel subtypes do opioid receptors couple? Do opioid receptors couple to Ca2+ channels through direct G protein interactions? Does the opioid-induced inhibition of vesicular release occur through modulation of multiple effectors? We are attempting to answer these questions by expressing cloned opioid receptors in GH3 cells. Using this well characterized system we can study the entire opioid signal transduction process from ligand-receptor interaction to G protein-effector coupling and subsequent inhibition of vesicular release.
阿片类药物可调节众多中枢和外周过程,包括痛觉、神经内分泌分泌和免疫反应。阿片类药物信号从受体通过G蛋白转导至各种不同的效应器。在转导过程的各个层面均存在异质性。存在多种内源性配体,它们对至少三种不同的阿片受体(μ、δ、κ)具有不同的选择性。由阿片受体激活的G蛋白通常属于对百日咳毒素敏感的Gi/Go类,但也存在一些阿片类药物作用被认为涉及Gq和对霍乱毒素敏感的G蛋白。更复杂的是,阿片受体的作用可能由G蛋白α亚基和/或βγ亚基介导。在G蛋白激活后,已知有几种效应器可协调阿片类药物信号。例如,阿片受体的激活会增加磷脂酰肌醇周转率、激活钾通道并降低腺苷酸环化酶和钙通道活性。这些效应器中的每一种都表现出相当大的异质性。在本综述中,我们研究了阿片类药物信号转导机制。出现了几个重要问题:为什么具有相似结合亲和力的阿片类药物配体在功能测定中具有不同的效力?阿片受体与哪些钙通道亚型偶联?阿片受体是否通过直接的G蛋白相互作用与钙通道偶联?阿片类药物诱导的囊泡释放抑制是否通过多种效应器的调节发生?我们正试图通过在GH3细胞中表达克隆的阿片受体来回答这些问题。利用这个特征明确的系统,我们可以研究从配体 - 受体相互作用到G蛋白 - 效应器偶联以及随后的囊泡释放抑制的整个阿片类药物信号转导过程。